These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20140758)

  • 21. Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis.
    Donahue KE; Schulman ER; Gartlehner G; Jonas BL; Coker-Schwimmer E; Patel SV; Weber RP; Bann CM; Viswanathan M
    J Gen Intern Med; 2019 Oct; 34(10):2232-2245. PubMed ID: 31388915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection and perception of methotrexate treatment information in people with rheumatoid arthritis.
    Leonardo N; Lester S; Graham M; Barrett C; Whittle S; Rowett D; Buchbinder R; Hill CL
    Int J Rheum Dis; 2020 Jun; 23(6):805-812. PubMed ID: 32537893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trials to establish methotrexate as a therapy for rheumatoid arthritis.
    Coury FF; Weinblatt ME
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S9-12. PubMed ID: 21044426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review.
    Curtis JR; Bykerk VP; Aassi M; Schiff M
    J Rheumatol; 2016 Nov; 43(11):1997-2009. PubMed ID: 27803341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis.
    Mota LMHD; Kakehasi AM; Gomides APM; Duarte ALBP; Cruz BA; Brenol CV; de Albuquerque CP; Castelar Pinheiro GDR; Laurindo IMM; Pereira IA; Bertolo MB; Ubirajara Silva de Souza MPG; de Freitas MVC; Louzada-Júnior P; Xavier RM; Giorgi RDN
    Adv Rheumatol; 2018 May; 58(1):2. PubMed ID: 30657071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study.
    Branco JC; Barcelos A; de Araújo FP; Sequeira G; Cunha I; Patto JV; Oliveira M; Mateus MP; Couto M; Nero P; Pinto P; Monteiro P; Castelão W; Félix J; Ferreira D; Almeida J; Silva MJ
    Adv Ther; 2016 Jan; 33(1):46-57. PubMed ID: 26724937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study).
    van Aken J; Heimans L; Gillet-van Dongen H; Visser K; Ronday HK; Speyer I; Peeters AJ; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2014 Feb; 73(2):396-400. PubMed ID: 23334213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
    Gaujoux-Viala C; Smolen JS; Landewé R; Dougados M; Kvien TK; Mola EM; Scholte-Voshaar M; van Riel P; Gossec L
    Ann Rheum Dis; 2010 Jun; 69(6):1004-9. PubMed ID: 20447954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on methotrexate.
    Braun J; Rau R
    Curr Opin Rheumatol; 2009 May; 21(3):216-23. PubMed ID: 19373092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
    Bakker MF; Jacobs JW; Welsing PM; Verstappen SM; Tekstra J; Ton E; Geurts MA; van der Werf JH; van Albada-Kuipers GA; Jahangier-de Veen ZN; van der Veen MJ; Verhoef CM; Lafeber FP; Bijlsma JW;
    Ann Intern Med; 2012 Mar; 156(5):329-39. PubMed ID: 22393128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting methotrexate resistance in rheumatoid arthritis patients.
    Yu MB; Firek A; Langridge WHR
    Inflammopharmacology; 2018 Jun; 26(3):699-708. PubMed ID: 29532212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.
    Kapetanovic MC; Nagel J; Nordström I; Saxne T; Geborek P; Rudin A
    Vaccine; 2017 Feb; 35(6):903-908. PubMed ID: 28081972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?
    McLean-Tooke A; Aldridge C; Waugh S; Spickett GP; Kay L
    Rheumatology (Oxford); 2009 Aug; 48(8):867-71. PubMed ID: 19447771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.
    Whittle SL; Hughes RA
    Rheumatology (Oxford); 2004 Mar; 43(3):267-71. PubMed ID: 14963199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
    Emery P; Fleischmann RM; Moreland LW; Hsia EC; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel BA; Doyle MK; Visvanathan S; Xu W; Rahman MU
    Arthritis Rheum; 2009 Aug; 60(8):2272-83. PubMed ID: 19644849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systemic review and meta-analysis of the clinical efficacy and safety of total glucosides of peony combined with methotrexate in rheumatoid arthritis.
    Feng ZT; Xu J; He GC; Cai SJ; Li J; Mei ZG
    Clin Rheumatol; 2018 Jan; 37(1):35-42. PubMed ID: 28748514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence to current recommendations on the use of methotrexate in rheumatoid arthritis in Italy: results from the MARI study.
    Manara M; Bianchi G; Bruschi E; Azzolini V; Belai Beyene N; Corbanese S; De Gennaro F; Martin-Martin LS; Molica Colella AB; Pozzi MR; Romeo N; Rossini T; Severino A; Sinigaglia L
    Clin Exp Rheumatol; 2016; 34(3):473-9. PubMed ID: 27050478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.